Biolinq has secured $100 million in Series C funding to further develop its biosensor platform, which includes the first intradermal glucose sensor that integrates activity and sleep data into a single wearable device. The funding will support the company’s commercial readiness and regulatory approval efforts.
Biolinq’s glucose sensor, worn on the upper forearm, provides real-time feedback through a color-changing indicator light. The company has completed its pivotal trial and submitted its investigational device for FDA regulatory review. The wearable biosensor utilizes electrochemical sensors to continuously measure glucose levels just beneath the skin’s surface.
This funding round accelerates Biolinq’s mission to inspire healthier living by providing deeper insights into a person’s metabolic health, with a focus on type 2 diabetes technology.
Follow MEDWIRE.AI for updates on diabetes device innovations.
